keyword
https://read.qxmd.com/read/38704603/loss-of-heterozygosity-impacts-mhc-expression-on-the-immune-microenvironment-in-cdk12-mutated-prostate-cancer
#1
JOURNAL ARTICLE
William Lautert-Dutra, Camila M Melo, Luiz P Chaves, Cheryl Crozier, Fabiano P Saggioro, Rodolfo B Dos Reis, Jane Bayani, Sandro L Bonatto, Jeremy A Squire
BACKGROUND: In prostate cancer (PCa), well-established biomarkers such as MSI status, TMB high, and PDL1 expression serve as reliable indicators for favorable responses to immunotherapy. Recent studies have suggested a potential association between CDK12 mutations and immunotherapy response; however, the precise mechanisms through which CDK12 mutation may influence immune response remain unclear. A plausible explanation for immune evasion in this subset of CDK12-mutated PCa may be reduced MHC expression...
May 4, 2024: Molecular Cytogenetics
https://read.qxmd.com/read/38700055/hepatocellular-carcinoma-after-direct-acting-antivirals-for-hepatitis-c-is-associated-with-kir-hla-types-predicting-weak-nk-cell-mediated-immunity
#2
JOURNAL ARTICLE
James C Ryan, Christina Haight, Erene C Niemi, Joshua D Grab, Jennifer L Dodge, Lewis L Lanier, Alexander Monto
BACKGROUND AND AIMS: Second-generation direct-acting antivirals (2G DAA) to cure HCV have led to dramatic clinical improvements. HCV-associated hepatocellular carcinoma (HCC), however, remains common. Impaired immune tumor surveillance may play a role in HCC development. Our cohort evaluated the effects of innate immune types and clinical variables on outcomes including HCC. METHODS: Participants underwent full HLA class I/KIR typing and long-term HCV follow-up...
May 3, 2024: European Journal of Immunology
https://read.qxmd.com/read/38699870/assessment-of-cancer-cell-expressed-hla-class-i-molecules-and-their-immunopathological-implications
#3
REVIEW
Terufumi Kubo, Shiori Asano, Kenta Sasaki, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Toshihiko Torigoe
Immunotherapy using immune checkpoint inhibitors (ICIs) has shown superior efficacy compared with conventional chemotherapy in certain cancer types, establishing immunotherapy as the fourth standard treatment alongside surgical intervention, chemotherapy, and radiotherapy. In cancer immunotherapy employing ICIs, CD8-positive cytotoxic T lymphocytes are recognized as the primary effector cells. For effective clinical outcomes, it is essential that the targeted cancer cells express HLA class I molecules to present antigenic peptides derived from the tumor...
May 2024: HLA
https://read.qxmd.com/read/38695604/final-outcomes-analysis-of-the-cell-product-sqz-pbmc-hpv-phase-1-trial-in-incurable-hpv16-solid-tumors-shows-improved-overall-survival-in-patients-with-increased-cd8-t-cell-tumor-infiltration
#4
JOURNAL ARTICLE
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Baranda, Antonio Jimeno
Cancer vaccines strive to induce robust, antigen-targeted, T-cell-mediated immune responses but have struggled to produce meaningful regression in solid tumors. An autologous cell vaccine, SQZ-PBMC-HPV, was developed by SQZ Biotechnologies using microfluidic squeezing technology to load PBMCs with HPV16 E6 and E7 antigens in HLA-A*02+ patients. The SQZ-PBMC-HPV-101 Phase 1 trial (NCT04084951) enrolled patients with incurable HPV16+ cancers. Here, we present a post hoc analysis of the relationship between Posttreatment CD8+ T cell infiltration and patient outcomes...
May 2, 2024: Molecular Carcinogenesis
https://read.qxmd.com/read/38693726/impacts-of-tumor-microenvironment-during-neoadjuvant-chemotherapy-in-patients-with-esophageal-squamous-cell-carcinoma
#5
JOURNAL ARTICLE
Kotaro Sugawara, Takashi Fukuda, Chiaki Murakami, Daiji Oka, Takako Yoshii, Gulanbar Amori, Kumiko Ishibashi, Yasuhito Kobayashi, Hiroki Hara, Hiroaki Kanda, Noriko Motoi
With the advent of immune checkpoint inhibitors (ICIs), a better understanding of tumor microenvironment (TME) is becoming crucial in managing esophageal squamous cell carcinoma (ESCC) patients. We investigated the survival impact of TME status and changes in patients with ESCC who underwent neoadjuvant chemotherapy (NAC) followed by surgery (n = 264). We examined immunohistochemical status (CD4+ , CD8+ , CD20+ , Foxp3+ , HLA class-1+ , CD204+ , and programmed death ligand-1 [PD-L1+ ]) on 264 pre-NAC and 204 paired post-NAC specimens...
May 1, 2024: Cancer Science
https://read.qxmd.com/read/38693538/genomic-landscape-and-distinct-molecular-subtypes-of-primary-testicular-lymphoma
#6
JOURNAL ARTICLE
Weilong Zhang, Ping Yang, Yaru Yang, Shuozi Liu, Yongdeng Xu, Chaoling Wu, Jing Wang, Cuiling Liu, Hui Liu, Shuangshuang Li, Wei Huang, Hongmei Jing
Primary testicular lymphoma (PTL) is a rare lymphoma predominantly occurring in the elderly male population. It is characterized by a limited response to treatment and a heightened tendency towards relapse. Histologically, approximately 90% of PTL cases are classified as diffuse large B-cell lymphomas (DLBCL). Genetic features of PTL were delineated in a limited scope within several independent studies. Some of the articles which analyzed the genetic characterization of DLBCL have incorporated PTL samples, but these have been constrained by small sample sizes...
May 1, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38690288/self-sufficient-primary-natural-killer-cells-engineered-to-express-t-cell-receptors-and-interleukin-15-exhibit-improved-effector-function-and-persistence
#7
JOURNAL ARTICLE
Els P van Hees, Laura T Morton, Dennis F G Remst, Anne K Wouters, Astrid Van den Eynde, J H Frederik Falkenburg, Mirjam H M Heemskerk
BACKGROUND: NK cells can be genetically engineered to express a transgenic T-cell receptor (TCR). This approach offers an alternative strategy to target heterogenous tumors, as NK:TCR cells can eradicate both tumor cells with high expression of HLA class I and antigen of interest or HLA class I negative tumors. Expansion and survival of NK cells relies on the presence of IL-15. Therefore, autonomous production of IL-15 by NK:TCR cells might improve functional persistence of NK cells. Here we present an optimized NK:TCR product harnessed with a construct encoding for soluble IL-15 (NK:TCR/IL-15), to support their proliferation, persistence and cytotoxic capabilities...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38687221/case-328
#8
JOURNAL ARTICLE
Cristina Agostinis, Elide Lupi
A 45-year-old female patient with diffuse osteoarticular pain, particularly low back pain, was referred by a rheumatologist for an updated radiologic evaluation. The patient had experienced these symptoms for many years and was diagnosed with human leukocyte antigen B27-negative spondyloarthritis approximately 11 years prior, based on findings of bilateral erosive sacroiliitis at pelvic radiography (Fig 1A) and bone scintigraphy with technetium 99m methylene diphosphonate (Fig 1B). After 3 years of treatment with a tumor necrosis factor-α inhibitor (adalimumab), which was effective for pain, the patient was lost to follow-up...
April 2024: Radiology
https://read.qxmd.com/read/38684865/identification-and-affinity-enhancement-of-t-cell-receptor-targeting-a-kras-g12v-cancer-neoantigen
#9
JOURNAL ARTICLE
Mengyu Zhang, Wei Xu, Lingjie Luo, Fenghui Guan, Xiangyao Wang, Pei Zhu, Jianhua Zhang, Xuyu Zhou, Feng Wang, Sheng Ye
Neoantigens derived from somatic mutations in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), the most frequently mutated oncogene, represent promising targets for cancer immunotherapy. Recent research highlights the potential role of human leukocyte antigen (HLA) allele A*11:01 in presenting these altered KRAS variants to the immune system. In this study, we successfully generate and identify murine T-cell receptors (TCRs) that specifically recognize KRAS8-16 G12V from three predicted high affinity peptides...
April 29, 2024: Communications Biology
https://read.qxmd.com/read/38681068/construction-of-an-immunogenic-cell-death-related-gene-signature-and-genetic-subtypes-for-predicting-prognosis-immune-microenvironments-and-drug-sensitivity-in-hepatocellular-carcinoma
#10
JOURNAL ARTICLE
Shuo Li, Tingyu Zhang, Xin Sun, Xiaoke Li
PURPOSE: Immunogenic cell death (ICD) is a type of regulated cell death that modifies the immune response by releasing DAMPs or danger signals. Herein, we aimed to develop an ICD-related predictive model for patients with hepatocellular carcinoma (HCC) and investigate its applicability for predicting prognostic outcomes and immunotherapeutic responses. METHODS: Differentially expressed genes of ICD were identified in the HCC and normal liver samples. A prognostic risk model and a nomogram containing clinicopathological features were created...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38677758/aldehyde-dehydrogenese-1-high-cancer-stem-like-cells-cancer-initiating-cells-escape-from-cytotoxic-t-lymphocytes-due-to-lower-expression-of-human-leukocyte-antigen-class-1
#11
JOURNAL ARTICLE
Tomohide Shirosaki, Noriko Kawai, Yuma Ebihara, Aiko Murai, Terufumi Kubo, Rena Morita, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Toshiaki Shichinohe, Yoshihiko Hirohashi, Satoshi Hirano, Toshihiko Torigoe
BACKGROUND/AIM: Human gastric cancer stem-like cells (CSCs)/cancer-initiating cells can be identified as aldehyde dehydrogenase-high (ALDHhigh ) cells. Cancer immunotherapy employing immune checkpoint blockade has been approved for advanced gastric cancer cases. However, the effectiveness of cancer immunotherapy against gastric CSCs/CICs remains unclear. This study aimed to investigate the susceptibility of gastric CSCs/CICs to immunotherapy. MATERIALS AND METHODS: Gastric CSCs/CICs were isolated as ALDHhigh cells using the human gastric cancer cell line, MKN-45...
May 2024: Anticancer Research
https://read.qxmd.com/read/38675774/immunoinformatics-design-and-in-vivo-immunogenicity-evaluation-of-a-conserved-ctl-multi-epitope-vaccine-targeting-hpv16-e5-e6-and-e7-proteins
#12
JOURNAL ARTICLE
Ni Guo, Zhixin Niu, Zhiling Yan, Weipeng Liu, Lei Shi, Chuanyin Li, Yufeng Yao, Li Shi
Human papillomavirus type 16 (HPV16) infection is responsible for more than 50% of global cervical cancer cases. The development of a vaccine based on cytotoxic T-lymphocyte (CTL) epitopes is a promising strategy for eliminating pre-existing HPV infections and treating patients with cervical cancer. In this study, an immunoinformatics approach was used to predict HLA-I-restricted CTL epitopes in HPV16 E5, E6, and E7 proteins, and a set of conserved CTL epitopes co-restricted by human/murine MHCs was screened and characterized, with the set containing three E5, four E6, and four E7 epitopes...
April 9, 2024: Vaccines
https://read.qxmd.com/read/38675381/autopepvax-a-novel-machine-learning-based-program-for-vaccine-design-application-to-a-pan-cancer-vaccine-targeting-egfr-missense-mutations
#13
JOURNAL ARTICLE
Enrico Bautista, Young Hyun Jung, Manuela Jaramillo, Harrish Ganesh, Aryaan Varma, Kush Savsani, Sivanesan Dakshanamurthy
The current epitope selection methods for peptide vaccines often rely on epitope binding affinity predictions, prompting the need for the development of more sophisticated in silico methods to determine immunologically relevant epitopes. Here, we developed AutoPepVax to expedite and improve the in silico epitope selection for peptide vaccine design. AutoPepVax is a novel program that automatically identifies non-toxic and non-allergenic epitopes capable of inducing tumor-infiltrating lymphocytes by considering various epitope characteristics...
March 26, 2024: Pharmaceuticals
https://read.qxmd.com/read/38672562/investigating-the-role-of-snai1-and-zeb1-expression-in-prostate-cancer-progression-and-immune-modulation-of-the-tumor-microenvironment
#14
JOURNAL ARTICLE
William Lautert-Dutra, Camila Morais Melo, Luiz Paulo Chaves, Francisco Cesar Sousa, Cheryl Crozier, Dan Dion, Filipe S Avante, Fabiano Pinto Saggioro, Rodolfo Borges Dos Reis, Leticia Fröhlich Archangelo, Jane Bayani, Jeremy A Squire
Prostate cancer (PCa) is an immunologically cold tumor and the molecular processes that underlie this behavior are poorly understood. In this study, we investigated a primary cohort of intermediate-risk PCa ( n = 51) using two NanoString profiling panels designed to study cancer progression and immune response. We identified differentially expressed genes (DEGs) and pathways associated with biochemical recurrence (BCR) and clinical risk. Confirmatory analysis was performed using the TCGA-PRAD cohort. Noteworthy DEGs included collagens such as COL1A1 , COL1A2 , and COL3A1 ...
April 12, 2024: Cancers
https://read.qxmd.com/read/38672472/lingering-effects-of-early-institutional-rearing-and-cytomegalovirus-infection-on-the-natural-killer-cell-repertoire-of-adopted-adolescents
#15
JOURNAL ARTICLE
Elizabeth K Wood, Brie M Reid, Dagna S Sheerar, Bonny Donzella, Megan R Gunnar, Christopher L Coe
Adversity during infancy can affect neurobehavioral development and perturb the maturation of physiological systems. Dysregulated immune and inflammatory responses contribute to many of the later effects on health. Whether normalization can occur following a transition to more nurturing, benevolent conditions is unclear. To assess the potential for recovery, blood samples were obtained from 45 adolescents adopted by supportive families after impoverished infancies in institutional settings (post-institutionalized, PI)...
April 9, 2024: Biomolecules
https://read.qxmd.com/read/38672132/t-cell-receptor-directed-bispecific-t-cell-engager-targeting-mhc-linked-ny-eso-1-for-tumor-immunotherapy
#16
JOURNAL ARTICLE
Yiming Li, Wenbin Zhao, Ying Shen, Yingchun Xu, Shuqing Chen, Liqiang Pan
Antibody-based bispecific T cell engagers (TCEs) that redirect T cells to kill tumor cells have shown a promising therapeutic effect on hematologic malignancies. However, tumor-specific targeting is still a challenge for TCEs, impeding the development of TCEs for solid tumor therapy. The major histocompatibility complex (MHC) presents almost all intracellular peptides (including tumor-specific peptides) on the cell surface to be scanned by the TCR on T cells. With the premise of choosing optimal peptides, the final complex peptide-MHC could be the tumor-specific target for TCEs...
April 1, 2024: Biomedicines
https://read.qxmd.com/read/38671743/autoepicollect-a-novel-machine-learning-based-gui-software-for-vaccine-design-application-to-pan-cancer-vaccine-design-targeting-pik3ca-neoantigens
#17
JOURNAL ARTICLE
Madhav Samudrala, Sindhusri Dhaveji, Kush Savsani, Sivanesan Dakshanamurthy
Previous epitope-based cancer vaccines have focused on analyzing a limited number of mutated epitopes and clinical variables preliminarily to experimental trials. As a result, relatively few positive clinical outcomes have been observed in epitope-based cancer vaccines. Further efforts are required to diversify the selection of mutated epitopes tailored to cancers with different genetic signatures. To address this, we developed the first version of AutoEpiCollect, a user-friendly GUI software, capable of generating safe and immunogenic epitopes from missense mutations in any oncogene of interest...
March 27, 2024: Bioengineering
https://read.qxmd.com/read/38670548/highlight-of-2023-from-fundamental-studies-to-clinical-trials-the-importance-of-nk-cells-against-cancer
#18
JOURNAL ARTICLE
Capucine Bourel, Sylvie Lesage
In this article for the Highlights of 2023 Series, we discuss how various factors affect the ability of natural killer (NK) cells to fight tumors. For instance, tumor cells can hinder NK cell function by reducing surface protrusions or increasing HLA-E expression via platelets. Lower UTX protein levels in male NK cells also decrease their cytotoxicity compared with females. Fortunately, recent advancements in therapeutic approaches have emerged, including the development of a comprehensive atlas of NK cell heterogeneity within the tumor microenvironment, as well as a trispecific engager molecule that has shown promise in enhancing the anti-tumor functions of NK cells...
April 26, 2024: Immunology and Cell Biology
https://read.qxmd.com/read/38669788/the-tumor-immune-composition-of-mismatch-repair-deficient-and-epstein-barr-virus-positive-gastric-cancer-a-systematic-review
#19
REVIEW
J Bos, T S Groen-van Schooten, C P Brugman, F S Jamaludin, H W M van Laarhoven, S Derks
BACKGROUND: Gastric cancer (GC), known for its unfavorable prognosis, has been classified in four distinct molecular subtypes. These subtypes not only exhibit differences in their genome and transcriptome but also in the composition of their tumor immune microenvironment. The microsatellite instable (MSI) and Epstein-Barr virus (EBV) positive GC subtypes show clear clinical benefits from immune checkpoint blockade, likely due to a neoantigen-driven and virus-driven antitumor immune response and high expression of immune checkpoint molecule PD-L1...
April 20, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38669064/spatial-profiling-of-ovarian-carcinoma-and-tumor-microenvironment-evolution-under-neoadjuvant-chemotherapy
#20
JOURNAL ARTICLE
Elisa Yaniz-Galende, Qinghe Zeng, Juan Francisco Grau-Bejar, Christophe Klein, Félix Blanc-Durand, Audrey Le Formal, Eric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle Ray-Coquard, Florence Joly, Gwenaël Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamichhane, Diana Bello Roufai, Justine Gantzer, Etienne Rouleau, Catherine Genestie, Alexandra Leary
PURPOSE: Immune tumor microenvironment (iTME) determines ovarian cancer development. This study investigates changes in HLA-I expression, CD8+/Foxp3 ratio, CD8+ cells and coregulators density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes. EXPERIMENTAL DESIGN: Multiplexed immune profiling and cell clustering analysis was performed on paired matched OC samples to characterize the iTME at diagnosis and under NACT from patients enrolled in the CHIVA trial (NCT01583322)...
April 26, 2024: Clinical Cancer Research
keyword
keyword
118202
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.